• Treffer 1 von 1
Zurück zur Trefferliste

Analysis of a multi-component multi-stage malaria vaccine candidate—tackling the cocktail challenge

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-173092
  • Combining key antigens from the different stages of the P. falciparum life cycle in the context of a multi-stage-specific cocktail offers a promising approach towards the development of a malaria vaccine ideally capable of preventing initial infection, the clinical manifestation as well as the transmission of the disease. To investigate the potential of such an approach we combined proteins and domains (11 in total) from the pre-erythrocytic, blood and sexual stages of P. falciparum into a cocktail of four different components recombinantlyCombining key antigens from the different stages of the P. falciparum life cycle in the context of a multi-stage-specific cocktail offers a promising approach towards the development of a malaria vaccine ideally capable of preventing initial infection, the clinical manifestation as well as the transmission of the disease. To investigate the potential of such an approach we combined proteins and domains (11 in total) from the pre-erythrocytic, blood and sexual stages of P. falciparum into a cocktail of four different components recombinantly produced in plants. After immunization of rabbits we determined the domain-specific antibody titers as well as component-specific antibody concentrations and correlated them with stage specific in vitro efficacy. Using purified rabbit immune IgG we observed strong inhibition in functional in vitro assays addressing the pre-erythrocytic (up to 80%), blood (up to 90%) and sexual parasite stages (100%). Based on the component-specific antibody concentrations we calculated the IC50 values for the pre-erythrocytic stage (17–25 μg/ml), the blood stage (40–60 μg/ml) and the sexual stage (1.75 μg/ml). While the results underline the feasibility of a multi-stage vaccine cocktail, the analysis of component-specific efficacy indicates significant differences in IC50 requirements for stage-specific antibody concentrations providing valuable insights into this complex scenario and will thereby improve future approaches towards malaria vaccine cocktail development regarding the selection of suitable antigens and the ratios of components, to fine tune overall and stage-specific efficacy.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Alexander Boes, Holger Spiegel, Nadja Voepel, Gueven Edgue, Veronique Beiss, Stephanie Kapelski, Rolf Fendel, Matthias Scheuermayer, Gabriele Pradel, Judith M. Bolscher, Marije C. Behet, Koen J. Dechering, Cornelus C. Hermsen, Robert W. Sauerwein, Stefan Schillberg, Andreas Reimann, Rainer Fischer
URN:urn:nbn:de:bvb:20-opus-173092
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Institut für Molekulare Infektionsbiologie
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):PLoS ONE
Erscheinungsjahr:2015
Band / Jahrgang:10
Heft / Ausgabe:7
Seitenangabe:e0131456
Originalveröffentlichung / Quelle:PLoS ONE 10(7): e0131456 (2015). DOI: 10.1371/journal.pone.0131456
DOI:https://doi.org/10.1371/journal.pone.0131456
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten
Freie Schlagwort(e):P. falciparum; antibodies; malaria; vaccines
Datum der Freischaltung:28.11.2018
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International